論文

国際誌
2022年

Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis.

PloS one
  • Yasuhiko Hattori
  • Kazuhiko Kurozumi
  • Yoshihiro Otani
  • Atsuhito Uneda
  • Nobushige Tsuboi
  • Keigo Makino
  • Shuichiro Hirano
  • Kentaro Fujii
  • Yusuke Tomita
  • Tetsuo Oka
  • Yuji Matsumoto
  • Yosuke Shimazu
  • Hiroyuki Michiue
  • Hiromi Kumon
  • Isao Date
  • 全て表示

17
8
開始ページ
e0273242
終了ページ
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1371/journal.pone.0273242

Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) is a tumor suppressor and its overexpression has been shown to exert anti-tumor effects as a therapeutic target gene in many human cancers. Recently, we demonstrated the anti-glioma effects of an adenoviral vector carrying REIC/Dkk-3 with the super gene expression system (Ad-SGE-REIC). Anti-vascular endothelial growth factor treatments such as bevacizumab have demonstrated convincing therapeutic advantage in patients with glioblastoma. However, bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. In this study, we examined the effects of Ad-SGE-REIC on glioma treated with bevacizumab. Ad-SGE-REIC treatment resulted in a significant reduction in the number of invasion cells treated with bevacizumab. Western blot analyses revealed the increased expression of several endoplasmic reticulum stress markers in cells treated with both bevacizumab and Ad-SGE-REIC, as well as decreased β-catenin protein levels. In malignant glioma mouse models, overall survival was extended in the combination therapy group. These results suggest that the combination therapy of Ad-SGE-REIC and bevacizumab exerts anti-glioma effects by suppressing the angiogenesis and invasion of tumors. Combined Ad-SGE-REIC and bevacizumab might be a promising strategy for the treatment of malignant glioma.

リンク情報
DOI
https://doi.org/10.1371/journal.pone.0273242
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/36006934
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409598
ID情報
  • DOI : 10.1371/journal.pone.0273242
  • PubMed ID : 36006934
  • PubMed Central 記事ID : PMC9409598

エクスポート
BibTeX RIS